Review Explores New Peptide-Based Treatments for Advanced Prostate Cancer

Prostate cancer remains a significant health challenge, particularly in its advanced stages. Recent advancements in understanding prostate cancer biology have paved the way for novel therapeutic strategies, notably those involving peptide-based agonists and antagonists. This review specifically addresses the current landscape and future potential of these new therapy modalities and approaches for treating advanced prostate cancer, evaluating both their efficacy and associated side effects.

The review highlighted that peptide-based treatment approaches, including combination therapies, have significantly improved the prognosis for patients with prostate cancer. While these novel therapies offer substantial benefits in controlling disease progression, they are frequently accompanied by extensive side-effects, impacting patient quality of life. Specifically, reported adverse events include sexual dysfunction, functional lesions of the liver and renal system, osteoporosis, anaemia, and diarrhoea. The authors concluded that despite the therapeutic advancements, the current challenge lies in mitigating these adverse effects, which can be severe enough to compromise overall patient well-being and treatment adherence. This underscores a critical need for developing agents that maintain high efficacy without the current burden of side effects.